These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 22991868)

  • 21. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study.
    Trefz FK; Burton BK; Longo N; Casanova MM; Gruskin DJ; Dorenbaum A; Kakkis ED; Crombez EA; Grange DK; Harmatz P; Lipson MH; Milanowski A; Randolph LM; Vockley J; Whitley CB; Wolff JA; Bebchuk J; Christ-Schmidt H; Hennermann JB;
    J Pediatr; 2009 May; 154(5):700-7. PubMed ID: 19261295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tetrahydrobiopterin responsiveness in patients with phenylketonuria.
    Pérez-Dueñas B; Vilaseca MA; Mas A; Lambruschini N; Artuch R; Gómez L; Pineda J; Gutiérrez A; Mila M; Campistol J
    Clin Biochem; 2004 Dec; 37(12):1083-90. PubMed ID: 15589814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in drug economy in Israel's health maintenance organizations in the wake of the National Health Insurance Law.
    Sax P
    Isr Med Assoc J; 2001 Aug; 3(8):605-9. PubMed ID: 11519388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential role of tetrahydrobiopterin in the treatment of maternal phenylketonuria.
    Trefz FK; Blau N
    Pediatrics; 2003 Dec; 112(6 Pt 2):1566-9. PubMed ID: 14654666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changing dietary practices in phenylketonuria.
    MacDonald A; Gökmen-Ozel H; Daly A
    Turk J Pediatr; 2009; 51(5):409-15. PubMed ID: 20112594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2011 Feb; (170):31-46. PubMed ID: 21323811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.
    Towse A; Garrison LP
    Pharmacoeconomics; 2010; 28(2):93-102. PubMed ID: 20085386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Updating the basket of health services].
    Israeli A; Chinitz DP
    Harefuah; 2003 Feb; 142(2):100-2, 159. PubMed ID: 12653041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of expanded mental health benefits on treatment costs.
    Sasso AT; Lurie IZ; Lee JU; Lindrooth RC
    J Ment Health Policy Econ; 2006 Mar; 9(1):25-33. PubMed ID: 16733269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tetrahydrobiopterin-responsive phenylketonuria: the New South Wales experience.
    Mitchell JJ; Wilcken B; Alexander I; Ellaway C; O'Grady H; Wiley V; Earl J; Christodoulou J
    Mol Genet Metab; 2005 Dec; 86 Suppl 1():S81-5. PubMed ID: 16091307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coverage with Evidence Development: applications and issues.
    Trueman P; Grainger DL; Downs KE
    Int J Technol Assess Health Care; 2010 Jan; 26(1):79-85. PubMed ID: 20059784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sapropterin. Phenylketonuria: for a minority of patients.
    Prescrire Int; 2010 Jun; 19(107):101-4. PubMed ID: 20738029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.
    Adamski J; Godman B; Ofierska-Sujkowska G; Osińska B; Herholz H; Wendykowska K; Laius O; Jan S; Sermet C; Zara C; Kalaba M; Gustafsson R; Garuolienè K; Haycox A; Garattini S; Gustafsson LL
    BMC Health Serv Res; 2010 Jun; 10():153. PubMed ID: 20529296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Public financing for off-label use of drugs].
    Hammerman A; Lipschitz Y; Pliskin J; Greenberg D
    Harefuah; 2011 Feb; 150(2):163-7, 204. PubMed ID: 22164947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reducing financial barriers to emergency obstetric care: experience of cost-sharing mechanism in a district hospital in Burkina Faso.
    Richard F; Ouédraogo C; Compaoré J; Dubourg D; De Brouwere V
    Trop Med Int Health; 2007 Aug; 12(8):972-81. PubMed ID: 17697092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Public drug expenditure in the Republic of Ireland.
    Barry M; Usher C; Tilson L
    Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):239-45. PubMed ID: 20545588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. End of life or end of the road? Are rising cancer costs sustainable? Is it time to consider alternative incentive and funding schemes?
    McGuire A; Drummond M; Martin M; Justo N
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):599-605. PubMed ID: 26176751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is sapropterin treatment suitable for all subjects with phenylketonuria?
    Doggrell SA
    Expert Opin Pharmacother; 2008 Jan; 9(1):145-7. PubMed ID: 18076346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tier 4 drugs and the fraying of the social compact.
    Lee TH; Emanuel EJ
    N Engl J Med; 2008 Jul; 359(4):333-5. PubMed ID: 18650510
    [No Abstract]   [Full Text] [Related]  

  • 40. Reform of the health care service system in Israel 1995-2000.
    Hart J
    World Hosp Health Serv; 2001; 37(3):9-11, 40, 42. PubMed ID: 11858011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.